Sargramostim for Injection

DRUG2 trials

Sponsors

Martin-Luther-Universität Halle-Wittenberg, University of Colorado, Denver

Conditions

Down SyndromeHead and Neck Squamous Cell Carcinoma

Phase 2

Tolerability and Efficacy of UV1 Vaccine in Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma Planned for First-line Treatment With Pembrolizumab

Martin-Luther-Universität Halle-WittenbergHead and Neck Squamous Cell Carcinoma

Start: 2021-08-02End: 2025-02-28Target: 75Updated: 2022-03-09

Trial to Evaluate Safety and Efficacy of GM-CSF /Sargramostim in Down Syndrome

WithdrawnNCT05482334

University of Colorado, DenverDown Syndrome

Start: 2023-10-23End: 2026-09-30Updated: 2025-04-02

Related Papers

Inflammation and limited adaptive immunity predict worse outcomes on immunotherapy in head and neck cancer

npj Precision Oncology2025-08-053 citations

UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial.

2025-04-112 citations

Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial

Frontiers in Oncology2024-02-0711 citations

Characterization of the T cell receptor repertoire and melanoma tumor microenvironment upon combined treatment with ipilimumab and hTERT vaccination.

2022-09-1117 citations